|
Volumn 13, Issue 6, 2007, Pages 515-516
|
How nuch "Spread" in AWP pricing is unlawful?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BLEOMYCIN SULFATE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
ETOPOSIDE;
GOSERELIN;
INFLIXIMAB;
PACLITAXEL;
SALBUTAMOL;
SALBUTAMOL SULFATE;
COST CONTROL;
DRUG COST;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MARKETING;
HEALTH CARE ACCESS;
HEALTH ECONOMICS;
HEALTH INSURANCE;
LAW SUIT;
MANAGED CARE;
NOTE;
PRESCRIPTION;
PROFIT;
PROSTATE CANCER;
REIMBURSEMENT;
ARTICLE;
COST;
ECONOMICS;
ETHICS;
HUMAN;
LEGAL ASPECT;
COSTS AND COST ANALYSIS;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
|
EID: 34548569154
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2007.13.6.515 Document Type: Note |
Times cited : (3)
|
References (5)
|